ACE2 and ACE in acute and chronic rejection after human heart transplantation.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Jan 2019
Historique:
received: 02 03 2018
revised: 07 09 2018
accepted: 01 10 2018
pubmed: 14 10 2018
medline: 20 7 2019
entrez: 14 10 2018
Statut: ppublish

Résumé

The authors sought to evaluate cardiac activity of angiotensin-converting enzyme (ACE) and ACE2 after heart transplantation (HT) and its relation with acute rejection (AR) and chronic allograft vasculopathy (CAV). The renin-angiotensin system is altered in heart failure and HT. However, ACE and ACE2 activities in post-HT acute and chronic rejection have not been previously studied. HT patients (n = 45) were included when appropriate serial endomyocardial biopsies (EMB) and coronary angiography were available for analysis. In 21 patients, three post-HT time points were selected for CAV study in EMB tissue: basal (0-3 wks), second (2-3 months) and third (4-5 months). At 10 years post-HT, CAV was evaluated by coronary angiography (CA) and patients were grouped by degree of CAV: 0-1, non-CAV (n = 15) and 2-3, CAV (n = 6). For the AR study, 28 HT patients with evidence of one EMB rejection at grade 3 and two EMB grade 1A and/or 1B rejections were selected. Post-HT, ACE2 activity was increased in the CAV group, compared to non-CAV. Patients with AR showed increased ACE, but not ACE2, activity. Our results suggest that early post-HT cardiac ACE2 activity may have an important role in CAV development. In contrast, ACE activity was increased in AR. The renin-angiotensin system seems to be altered after HT and strategies to balance the system may be useful.

Sections du résumé

OBJECTIVES OBJECTIVE
The authors sought to evaluate cardiac activity of angiotensin-converting enzyme (ACE) and ACE2 after heart transplantation (HT) and its relation with acute rejection (AR) and chronic allograft vasculopathy (CAV).
BACKGROUND BACKGROUND
The renin-angiotensin system is altered in heart failure and HT. However, ACE and ACE2 activities in post-HT acute and chronic rejection have not been previously studied.
METHODS METHODS
HT patients (n = 45) were included when appropriate serial endomyocardial biopsies (EMB) and coronary angiography were available for analysis. In 21 patients, three post-HT time points were selected for CAV study in EMB tissue: basal (0-3 wks), second (2-3 months) and third (4-5 months). At 10 years post-HT, CAV was evaluated by coronary angiography (CA) and patients were grouped by degree of CAV: 0-1, non-CAV (n = 15) and 2-3, CAV (n = 6). For the AR study, 28 HT patients with evidence of one EMB rejection at grade 3 and two EMB grade 1A and/or 1B rejections were selected.
RESULTS RESULTS
Post-HT, ACE2 activity was increased in the CAV group, compared to non-CAV. Patients with AR showed increased ACE, but not ACE2, activity.
CONCLUSIONS CONCLUSIONS
Our results suggest that early post-HT cardiac ACE2 activity may have an important role in CAV development. In contrast, ACE activity was increased in AR. The renin-angiotensin system seems to be altered after HT and strategies to balance the system may be useful.

Identifiants

pubmed: 30314840
pii: S0167-5273(18)31428-1
doi: 10.1016/j.ijcard.2018.10.002
pii:
doi:

Substances chimiques

Biomarkers 0
Peptidyl-Dipeptidase A EC 3.4.15.1
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

59-64

Informations de copyright

Copyright © 2018. Published by Elsevier B.V.

Auteurs

Maria Jose Soler (MJ)

Nephrology Department, Hospital del Mar. IMIM (Hospital del Mar Medical Research Institute). Barcelona, Spain; Nephrology Department, Hospital Universitari Vall d´Hebron, Barcelona, Spain. Electronic address: mjsoler01@gmail.com.

Montserrat Batlle (M)

Cardiovascular Institute, Hospital Clínic de Barcelona and Institut de Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Electronic address: mbatlle@clinic.cat.

Marta Riera (M)

Nephrology Department, Hospital del Mar. IMIM (Hospital del Mar Medical Research Institute). Barcelona, Spain.

Begoña Campos (B)

Department of Clinical Foundations, University of Barcelona, Spain.

José Tomás Ortiz-Perez (JT)

Cardiovascular Institute, Hospital Clínic de Barcelona and Institut de Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Lidia Anguiano (L)

Nephrology Department, Hospital del Mar. IMIM (Hospital del Mar Medical Research Institute). Barcelona, Spain.

Heleia Roca-Ho (H)

Nephrology Department, Hospital del Mar. IMIM (Hospital del Mar Medical Research Institute). Barcelona, Spain.

Marta Farrero (M)

Cardiovascular Institute, Hospital Clínic de Barcelona and Institut de Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Lluis Mont (L)

Cardiovascular Institute, Hospital Clínic de Barcelona and Institut de Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Julio Pascual (J)

Nephrology Department, Hospital del Mar. IMIM (Hospital del Mar Medical Research Institute). Barcelona, Spain.

Felix Perez-Villa (F)

Cardiovascular Institute, Hospital Clínic de Barcelona and Institut de Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH